Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study

被引：0

作者：

Morita, Atsuhiro ^{[1
]}

Tamaki, Nobuharu ^{[3
]}

Kobashi, Haruhiko ^{[5
]}

Mori, Nami ^{[6
,7
]}

Tsuji, Keiji ^{[6
,7
]}

Takaki, Shintaro ^{[6
,7
]}

Hasebe, Chitomi ^{[8
]}

Akahane, Takehiro ^{[9
]}

Ochi, Hironori ^{[10
]}

Mashiba, Toshie ^{[10
]}

Urawa, Naohito ^{[23
]}

Fujii, Hideki ^{[2
]}

Mitsuda, Akeri ^{[12
]}

Kondo, Masahiko ^{[13
]}

Ogawa, Chikara ^{[14
]}

Uchida, Yasushi ^{[15
]}

Narita, Ryoichi ^{[16
]}

Marusawa, Hiroyuki ^{[17
]}

Kubotsu, Yoshihito ^{[18
]}

Matsushita, Tomomichi ^{[19
]}

Shigeno, Masaya ^{[20
]}

Yoshida, Hideo ^{[4
]}

Tanaka, Katsuaki ^{[21
]}

Okamoto, Eisuke ^{[22
]}

Kasai, Toyotaka ^{[11
]}

Ishii, Toru ^{[24
]}

Okada, Kazuhiko ^{[25
]}

Kurosaki, Masayuki ^{[3
]}

Izumi, Namiki ^{[3
]}

机构：

[1] Japanese Red Cross Kyoto Daini, Dept Gastroenterol, Kyoto, Japan

[2] Japanese Red Cross Kyoto Daiichi Hosp, Dept Gastroenterol, Kyoto, Japan

[3] Musashino Red Cross Hosp, Dept Gastroenterologyand Hepatol, 1-26-1 Kyonan Cho, Musashino, Tokyo 1808610, Japan

[4] Japanese Red Cross Med Ctr, Dept Gastroenterol, Tokyo, Japan

[5] Japanese Red Cross Okayama Hosp, Dept Gastroenterol, Tokyo, Japan

[6] Hiroshima Red Cross Hosp, Dept Gastroenterol, Hiroshima, Japan

[7] Atom Bomb Survivors Hosp, Hiroshima, Japan

[8] Japanese Red Cross Asahikawa Hosp, Dept Gastroenterol, Asahikawa, Japan

[9] Ishinomaki Red Cross Hosp, Dept Gastroenterol, Ishinomaki, Japan

[10] Matsuyama Red Cross Hosp, Ctr Liver Biliary Pancreat Dis, Matsuyama, Japan

[11] Ise Red Cross Hosp, Dept Gastroenterol & Hepatol, Ise, Japan

[12] Tottori Red Cross Hosp, Dept Gastroenterol, Tottori, Japan

[13] Otsu Red Cross Hosp, Dept Gastroenterol, Otsu, Japan

[14] Takamatsu Red Cross Hosp, Dept Gastroenterol & Hepatol, Takamatsu, Japan

[15] Matsue Red Cross Hosp, Dept Gastroenterol, Matsue, Japan

[16] Oita Red Cross Hosp, Dept Gastroenterol, Oita, Japan

[17] Osaka Red Cross Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan

[18] Karatsu Red Cross Hosp, Dept Internal Med, Saga, Japan

[19] Japanese Red Cross Gifu Hosp, Dept Gastroenterol, Gifu, Japan

[20] Japanese Red Cross Nagasaki Genbaku Hosp, Dept Gastroenterol, Nagasaki, Japan

[21] Hatano Red Cross Hosp, Dept Gastroenterol, Hatano, Japan

[22] Masuda Red Cross Hosp, Dept Gastroenterol, Masuda, Japan

[23] Fukaya Red Cross Hosp, Dept Gastroenterol, Saitama, Japan

[24] Japanese Red Cross Akita Hosp, Dept Gastroenterol, Akita, Japan

[25] Toyama Red Cross Hosp, Dept Gastroenterol, Toyama, Japan

来源：

JGH OPEN | 2024年 / 8卷 / 04期

关键词：

chronic hepatitis C; cirrhosis; glecaprevir and pibrentasvir (GLE/PIB); treatment periods;

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background and aimIn patients with chronic hepatitis C, 8 weeks of glecaprevir and pibrentasvir (GLE/PIB) treatment for chronic hepatitis (non-cirrhosis) and 12 weeks for cirrhosis have been approved in Japan. However, whether 8 weeks of treatment for cirrhosis may reduce treatment efficacy has not been adequately investigated.MethodsThis prospective, nationwide, multicenter cohort study enrolled 1275 patients with chronic hepatitis C who received GLE/PIB therapy. The effect of liver fibrosis and treatment periods on the efficiency of GLE/PIB therapy was investigated. The primary endpoint was the sustained virological response (SVR) rate in patients with chronic hepatitis (non-cirrhosis) and cirrhosis. The association between treatment periods and liver fibrosis on the SVR after 12 weeks of treatment rate was investigated.ResultsThe SVR rates in patients with chronic hepatitis with 8 weeks of treatment, chronic hepatitis with 12 weeks of treatment, cirrhosis with 8 weeks of treatment, and cirrhosis with 12 weeks of treatment were 98.9% (800/809), 100% (87/87), 100% (166/166), and 99.1% (211/213), respectively, and were was not different among these groups (P = 0.4).ConclusionGLE/PIB therapy for chronic hepatitis C had high efficacy regardless of liver fibrosis status and treatment periods. Periods of GLE/PIB therapy could be chosen with available modalities, and high SVR rates could be achieved regardless of the decision. GLE/PIB therapy for chronic hepatitis C had high efficacy regardless of liver fibrosis status and treatment periods. Periods of GLE/PIB therapy could be chosen with available modalities, and high SVR rates could be achieved regardless of the decision. image

引用

页数：6

共 50 条

[1] Prospective multicenter study of glecaprevir plus pibrentasvir combination therapy for patients with chronic hepatitis C
Tamori, Akihiro
Iwasa, Motoo
Inoue, Kazuaki
Kagawa, Tatehiro
Takaguchi, Koichi
Minami, Masahito
Iwasaki, Yoshiaki
Nouso, Kazuhiro
Hoang, Hai
Enomoto, Masaru
Kawada, Norifumi
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E242 - E243
[2] Real-world efficacy and safety of glecaprevir/pibrentasvir in Japanese adolescents with chronic hepatitis C: a prospective multicenter study
Mizuochi, Tatsuki
Iwama, Itaru
Inui, Ayano
Ito, Yoshinori
Takaki, Yugo
Mushiake, Sotaro
Tokuhara, Daisuke
Ishige, Takashi
Ito, Koichi
Murakami, Jun
Hishiki, Haruka
Mikami, Hitoshi
Bessho, Kazuhiko
Kato, Ken
Yasuda, Ryosuke
Yamashita, Yushiro
Tanaka, Yasuhito
Tajiri, Hitoshi
JOURNAL OF GASTROENTEROLOGY, 2023, 58 (04) : 405 - 412
[3] Efficacy and safety of glecaprevir/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study
Kwan, Byung Soo
Kong, Sung Min
Shim, Sang Goon
Kim, Kwang Min
Yu, Gil Jong
Lee, Jae Jin
Kim, Jin Dong
ARAB JOURNAL OF GASTROENTEROLOGY, 2023, 24 (02) : 104 - 108
[4] Real-world efficacy and safety of glecaprevir/pibrentasvir in Japanese adolescents with chronic hepatitis C: a prospective multicenter study
Tatsuki Mizuochi
Itaru Iwama
Ayano Inui
Yoshinori Ito
Yugo Takaki
Sotaro Mushiake
Daisuke Tokuhara
Takashi Ishige
Koichi Ito
Jun Murakami
Haruka Hishiki
Hitoshi Mikami
Kazuhiko Bessho
Ken Kato
Ryosuke Yasuda
Yushiro Yamashita
Yasuhito Tanaka
Hitoshi Tajiri
Journal of Gastroenterology, 2023, 58 : 405 - 412
[5] Glecaprevir/Pibrentasvir (Mavyret) for the Treatment of Chronic Hepatitis C
Grover, Anupriya
Erlich, Deborah R.
AMERICAN FAMILY PHYSICIAN, 2018, 98 (10) : 601 - 602
[6] Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection
Mensa, Federico J.
Lovell, Sandra
Pilot-Matias, Tami
Liu, Wei
FUTURE MICROBIOLOGY, 2019, 14 (02) : 89 - 110
[7] SAFETY AND EFFICACY OF STATIN MANAGEMENT DURING GLECAPREVIR/PIBRENTASVIR TREATMENT FOR CHRONIC HEPATITIS C
Kwo, Paul
Jones, Peter
Barcomb, Lisa
Gathe, Joseph, Jr.
Yu, Yao
Dylla, Douglas
Porcalla, Ariel
Mensa, Federico
Toth, Peter
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1763 - 1763
[8] REAL-WORLD EXPERIENCE OF GLECAPREVIR/PIBRENTASVIR TREATMENT IN JAPANESE ADOLESCENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: A PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY
Mizuochi, Tatsuki
Iwama, Itaru
Inui, Ayano
Ito, Yoshinori
Takaki, Yugo
Mushiake, Sotaro
Tokuhara, Daisuke
Ishige, Takashi
Ito, Koichi
Murakami, Jun
Hishiki, Haruka
Mikami, Hitoshi
Bessho, Kazuhiko
Kato, Ken
Yasuda, Ryosuke
Yamashita, Yushiro
Tanaka, Yasuhito
Tajiri, Hitoshi
HEPATOLOGY, 2022, 76 : S1524 - S1525
[9] Glecaprevir plus pibrentasvir for treatment of hepatitis C
Carrion, Andres F.
Martin, Paul
EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (04) : 413 - 419
[10] Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults
Nehra, V
Rizza, S. A.
Temesgen, Z.
DRUGS OF TODAY, 2018, 54 (07) : 407 - 421

← 1 2 3 4 5 →